Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3994MR)

This product GTTS-WQ3994MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3994MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8818MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ12724MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ6818MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ6403MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ1376MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ13932MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ2640MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ245MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 14.18 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW